Skip to content

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

A Study of Bumetanide for the Treatment of Children With Autism Spectrum Disorder:a Randomized Double-blind Placebo-controlled Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03156153
Enrollment
120
Registered
2017-05-17
Start date
2017-05-24
Completion date
2019-07-10
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Brief summary

The investigators are going to carry out a randomized double-blind placebo-controlled trial to study the efficiency and mechanism of bumetanide on the treatment of children with Autism Spectrum Disorder.

Detailed description

In consideration of the increasing number of autistic children and poor intervention effect in China, it is an urgent to find some effective medicine. Some studies have reported bumetanide, a classic diuretic, could improve autistic behaviors in both animal model and humans; while the efficiency of bumetanide on Chinese autistic chilren is unkonwn and the underlying mechanisms remain unfolding. The investigators aim at investigating whether bumetanide would improve the clinical symptoms in Chinese children with autism within a safe dosage and further study the physiological mechanism beneath.The investigators will regularly assess the participants' autism-related symptoms during medication, as well as the adverse effects of each patient. The investigators will carry out genome-wide association analysis (GWAS) from blood sample, related metabolites in nervous system and compare the concentration of the neurotransmitter in autistic brain before and after 3 months' treatmeat,and also will collect the EEG signal in autistic chilldren when the participants performing certain tasks before and after 3 months' treatment.

Interventions

bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

DRUGPlacebo

placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

Sponsors

Shanghai Jiao Tong University School of Medicine
CollaboratorOTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

The patients, aged from 3 to 6 years old, were given the diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) , by a team of autism experts; Scores for Children Autism Rating Scale (CARS) were more than 30; Signed Informed Consents were provided by parents.

Exclusion criteria

Liver and kidney dysfunction; With a history of allergy to sulfa drugs; abnormal ECG; chromosomal abnormality; suffering from nervous system diseases (such as epilepsy, schizophrenia, and so on); using the melatonin treatment for sleep disorders or withdrawal less than three weeks.

Design outcomes

Primary

MeasureTime frameDescription
Childhood Autism Rating Scale(CARS)Day 0 and Day 90CARS is a behaviour-rating scale used to assess the presence and severity of the symptoms of autism spectrum disorder

Secondary

MeasureTime frameDescription
Chinese Communicative Development InventoryDay 0 and Day 90The Chinese Communicative Development Inventories (CCDI) is a questionnaire that is used to direct measures of the participants' language.Change between day 0 and day 90 of the result of the Chinese Communicative Development Inventory
Social Responsiveness Scale (SRS)Day 0 and Day 90SRS is a questionnaire used to assess the presence and severity of social impairment.
Autism Diagnostic Observation Schedule (ADOS)Day 0 and Day 90The ADOS is a structured play session conducted by clinicians, with the total score combines the Social and Communication domain items.
Short Sensory Profile ReportDay 0 and Day 90The Sensory Profile is a measure of children's responses to sensory events in daily life. The caregiver completes the Sensory Profile by assessing the frequency of the child's responses to certain sensory processing, modulation, and behavioral/emotional events as described in the 125 items.
Symbolic Play TestDay 0 and Day 90Symbolic Play Test is a nonverbal measure of symbolic functioning in participants aged 12-36 months. The test does not require any expressive speech, and is therefore appropriate for use with all participants with ASD. Participants are sequentially presented with four sets of toys, and their spontaneous manipulation of the objects is observed and recorded on a standardized checklist.
Clinical Global Impressions Scale (CGI)Day 0 and Day 90CGI is a scale used to assess the severity of the illness and the global improvement of the patient under intervention

Other

MeasureTime frameDescription
Multichannel EEG SignalsDay 0 and Day 90Change in brain Multichannel EEG signals
Genome wide association study from blood sampleDay 90Selection and study of susceptible genes
Analysis of metabolites from blood sampleDay 0 and Day 90Metabonomics research
MRI Structure Imaging and Spectrum imaging, data analysisDay 0 and Day 90Change of structure of the brain and the GABA-neurotransmitters in specific brain regions of the brain.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026